Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.

Seynnaeve B, Lee S, Borah S, Park Y, Pappo A, Kirkwood JM, Bahrami A.

Sci Rep. 2017 Apr 5;7:45704. doi: 10.1038/srep45704.

2.

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.

Bai X, Kong Y, Chi Z, Sheng X, Cui C, Wang X, Mao L, Tang B, Li S, Lian B, Yan X, Zhou L, Dai J, Guo J, Si L.

Clin Cancer Res. 2017 Oct 15;23(20):6120-6127. doi: 10.1158/1078-0432.CCR-17-0980. Epub 2017 Jul 18.

3.

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.

Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, Niccoli C, Basolo F, Fontanini G.

Virchows Arch. 2015 Aug;467(2):177-84. doi: 10.1007/s00428-015-1784-x. Epub 2015 Jun 9.

PMID:
26055532
4.

TERT promoter mutations in melanoma survival.

Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, Soriano V, Frank C, Traves V, Quecedo E, Sanjuan-Gimenez J, Hemminki K, Landi MT, Kumar R.

Int J Cancer. 2016 Jul 1;139(1):75-84. doi: 10.1002/ijc.30042. Epub 2016 Mar 2.

5.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D.

J Natl Cancer Inst. 2014 Sep 13;106(9). pii: dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep.

6.

Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.

Ofner R, Ritter C, Heidenreich B, Kumar R, Ugurel S, Schrama D, Becker JC.

J Cancer Res Clin Oncol. 2017 Apr;143(4):613-617. doi: 10.1007/s00432-016-2322-1. Epub 2016 Dec 18.

PMID:
27990595
7.

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.

Andrés-Lencina JJ, Rachakonda S, García-Casado Z, Srinivas N, Skorokhod A, Requena C, Soriano V, Kumar R, Nagore E.

Int J Cancer. 2019 Mar 1;144(5):1027-1036. doi: 10.1002/ijc.31780. Epub 2018 Oct 4.

PMID:
30070694
8.

TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.

Miyake Y, Adachi JI, Suzuki T, Mishima K, Araki R, Mizuno R, Nishikawa R.

J Neurooncol. 2019 Jan;141(1):131-138. doi: 10.1007/s11060-018-03016-8. Epub 2018 Nov 3.

PMID:
30392088
9.

Varying Mutational Alterations in Multiple Primary Melanomas.

Egberts F, Bohne AS, Krüger S, Hedderich J, Rompel R, Haag J, Röcken C, Hauschild A.

J Mol Diagn. 2016 Jan;18(1):75-83. doi: 10.1016/j.jmoldx.2015.07.010. Epub 2015 Nov 20.

PMID:
26607775
10.

TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.

Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, Korah R, Carling T, Bäckdahl M, Wang N, Juhlin CC, Larsson C.

Int J Mol Med. 2018 Sep;42(3):1675-1683. doi: 10.3892/ijmm.2018.3735. Epub 2018 Jun 20.

PMID:
29956721
11.

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.

Vallarelli AF, Rachakonda PS, André J, Heidenreich B, Riffaud L, Bensussan A, Kumar R, Dumaz N.

Oncotarget. 2016 Aug 16;7(33):53127-53136. doi: 10.18632/oncotarget.10634.

12.

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.

Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, Krist B, Post E, Zwarthoff EC, de Klein A, Verdijk RM; Rotterdam Ocular Melanoma Study Group.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):6024-30. doi: 10.1167/iovs.14-14901.

PMID:
25159205
13.

Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.

Vazquez Vde L, Vicente AL, Carloni A, Berardinelli G, Soares P, Scapulatempo C, Martinho O, Reis RM.

Melanoma Res. 2016 Apr;26(2):93-9. doi: 10.1097/CMR.0000000000000222.

PMID:
26709572
14.

TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.

Dubbink HJ, Bakels H, Post E, Zwarthoff EC, Verdijk RM.

J Neurooncol. 2014 Nov;120(2):267-72. doi: 10.1007/s11060-014-1553-8. Epub 2014 Jul 18.

PMID:
25035100
15.

Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.

Roh MR, Park KH, Chung KY, Shin SJ, Rha SY, Tsao H.

Am J Cancer Res. 2017 Jan 1;7(1):134-138. eCollection 2017.

16.

Melanomas of unknown primary frequently harbor TERT-promoter mutations.

Egberts F, Krüger S, Behrens HM, Bergner I, Papaspyrou G, Werner JA, Alkatout I, Haag J, Hauschild A, Röcken C.

Melanoma Res. 2014 Apr;24(2):131-6. doi: 10.1097/CMR.0000000000000048.

PMID:
24463461
17.

TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.

Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, Bahrami A.

Sci Rep. 2015 Jun 10;5:11200. doi: 10.1038/srep11200.

18.

Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, Townsley DM, Dumitriu B, Battiwalla M, Rezvani K, Young NS, Barrett AJ, Ito S.

Br J Haematol. 2016 Nov;175(3):427-439. doi: 10.1111/bjh.14244. Epub 2016 Jul 19.

19.

Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.

Li Y, Cheng HS, Chng WJ, Tergaonkar V.

Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14402-14407. Epub 2016 Nov 23.

20.

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K.

Acta Neuropathol. 2013 Aug;126(2):267-76. doi: 10.1007/s00401-013-1141-6. Epub 2013 Jun 14.

PMID:
23764841

Supplemental Content

Support Center